Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence
Marcos A Sanchez-Gonzalez, Jonna B Westover, Syed A A Rizvi, Joselit Torres, Gustavo Ferrer
Medical Research Archives, doi:10.18103/mra.v10i3.2752
Recently, the nasal cavity has been highlighted as an ideal route of administration for interventions as it is the portal of entry of the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The present study aimed to demonstrate the feasibility and efficacy of intranasally administered Chlorpheniramine Maleate (CPM) spray to treat coronavirus disease 2019 (COVID-19). Methods: The present study used a two-phase, non-clinical to clinical approach. The non-clinical phase evaluated CPM's antiviral activity against SARS-CoV-2 delta (B.1.617.2) strain via a highly differentiated three-dimensional in vitro model of normal, human-derived tracheal/bronchial epithelial cells. CPM was tested in duplicate inserts of the tissue models of the human airway. Virus yield reduction assays measured antiviral activity on day six after infection. For the clinical phase, COVID-19 symptomatic (polymerase chain reaction positive) patients were recruited and assigned to a 7-day CPM treatment (n=32) or placebo (PLB; n=13). Close safety monitoring of all patients was conducted before and after administering the drug. The primary outcomes monitored were time to symptom resolution (days), progression to hospitalization, emergency room visits, and symptoms of the severity of the disease using a visual analog scale (VAS) on a scale of 1-10 (no symptoms to worst symptoms). Results: The virus yielded a reduction in the assay such that the CPM solution log reduction value was 2.69 and Remdesivir 0.12, demonstrating much high antiviral activity of CPM. Results of the clinical phase demonstrate that VAS scores between the groups were evident after using CPM for two days (day 3). The CPM group VAS were significantly lower (P<0.001) starting from day three compared with day one. In contrast, there were no statistically significant (P>0.05) changes in the PLB during the 7-day treatment window. No subjects in the intervention group were hospitalized, while two in the PLB required hospitalization (15.4%; X2=5.15, P=0.023). Besides some mild discomfort felt by subjects immediately after applying the spray, the participants reported neither adverse reactions nor side effects.
Conclusion: If taken together, the results of the present two-phase study point towards the conclusion that CPM is an antiviral agent that can be administered intranasally to treat COVID-19 effectively.
References
Black, Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19, Cureus,
doi:10.7759/cureus.20980Blanco, Bonilla, Homma, Suzuki, Smith et al., Antihistamines and azithromycin as a treatment for COVID-19 on primary health care -A retrospective observational study in elderly patients, Pulm Pharmacol Ther,
doi:10.1016/j.pupt.2021.101989Branco, Yoshikawa, Pietrobon, Sato, Role of Histamine in Modulating the Immune Response and Inflammation, Mediators of Inflammation,
doi:10.1155/2018/9524075Doyle, Skoner, Gentile, Nasal cytokines as mediators of illness during the common cold, Current Allergy and Asthma Reports,
doi:10.1007/s11882-005-0034-8Eldanasory, Eljaaly, Memish, Tawfiq, Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101874Ferrer, Sanchez-Gonzalez, Effective Nasal Disinfection as an Overlooked Strategy in Our Fight against COVID-19, Ear Nose Throat J,
doi:10.1177/01455613211002929Galal, Hussein, Amin, Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score, The Egyptian Journal of Bronchology,
doi:10.1186/s43168-020-00049-4Graham, Temple, Obar, Mast Cells and Influenza A Virus: Association with Allergic Responses and Beyond, Review. Frontiers in Immunology,
doi:10.3389/fimmu.2015.00238Jia, Look, Shi, ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia, J Virol,
doi:10.1128/jvi.79.23.14614-14621.2005Kirkegaard, Secher, Borum, Mygind, Inhibition of histamine-induced nasal symptoms by the H1 antihistamine chlorpheniramine maleate: demonstration of topical effect, Br J Dis Chest,
doi:10.1016/0007-0971(83)90017-7Kumar, Cheng, A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2, Pharmazie,
doi:10.1691/ph.2021.0840Li, Zhang, Liu, Gu, Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases, Faseb j,
doi:10.1096/fj.202000502Mangal, Murari, Vashisht, Olfactory Dysfunction Among Asymptomatic Patients with SARS CoV2 Infection: A Case-Control Study, Indian J Otolaryngol Head Neck Surg,
doi:10.1007/s12070-021-02366-6Mostafa, Kandeil, Amme, FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals,
doi:10.3390/ph13120443Qin, Zhou, Hu, Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis,
doi:10.1093/cid/ciaa248Reznikov, Norris, Vashisht, Identification of antiviral antihistamines for COVID-19 repurposing, Biochem Biophys Res Commun,
doi:10.1016/j.bbrc.2020.11.095Sanchez-Gonzalez, Moskowitz, Issuree, Yatzkan, Rizvi et al., A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation, Infect Chemother
Sanchez-Gonzalez, Rizvi, Torres, Ferrer, A Randomized Controlled Pilot Trial to Test the Efficacy of Intranasal Chlorpheniramine Maleate With Xylitol for the Treatment of Allergic Rhinitis, Cureus,
doi:10.7759/cureus.14206Taha, Hall, Shortess, Rathbone, Barham, Treatment Protocol for COVID-19 Based on T2R Phenotype, Viruses,
doi:10.3390/v13030503Torres, Go, Camacho, Sanchez-Gonzalez, Ferrer, Chlorpheniramine Maleate Nasal Spray In COVID-19 Patients: Case Series, J Clin Exp Pharmacol,
doi:10.35248/2161-1459.21.10.275Van Toor, Buchwald, Stengele, Trenk, Gercek et al., Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally, International journal of clinical pharmacology and therapeutics,
doi:10.5414/cpp39173Westover, Ferrer, Vazquez, Bethencourt-Mirabal, Go, In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2, Cureus,
doi:10.7759/cureus.10501Wilson, Simpson, Ferreira, Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis, JCI Insight,
doi:10.1172/jci.insight.140289Wu, Liu, Sun, SARS-CoV-2triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury, Signal Transduction and Targeted Therapy,
doi:10.1038/s41392-021-00849-0Xu, Xia, Pu, The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses, Front Microbiol,
doi:10.3389/fmicb.2018.02643Zarkoob, Allué-Guardia, Chen, Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents, bioRxiv,
doi:10.1101/2021.05.11.443693{ 'indexed': {'date-parts': [[2024, 2, 15]], 'date-time': '2024-02-15T12:01:00Z', 'timestamp': 1707998460658},
'reference-count': 0,
'publisher': 'Knowledge Enterprise Journals',
'issue': '3',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2022]]},
'abstract': '<jats:p>Recently, the nasal cavity has been highlighted as an ideal route of administration '
'for interventions as it is the portal of entry of the severe acute respiratory syndrome '
'coronavirus (SARS-CoV-2). The present study aimed to demonstrate the feasibility and efficacy '
'of intranasally administered Chlorpheniramine Maleate (CPM) spray to treat coronavirus '
'disease 2019 (COVID-19). Methods: The present study used a two-phase, non-clinical to '
'clinical approach. The non-clinical phase evaluated CPM’s antiviral activity against '
'SARS-CoV-2 delta (B.1.617.2) strain via a highly differentiated three-dimensional in vitro '
'model of normal, human-derived tracheal/bronchial epithelial cells. CPM was tested in '
'duplicate inserts of the tissue models of the human airway. Virus yield reduction assays '
'measured antiviral activity on day six after infection. For the clinical phase, COVID-19 '
'symptomatic (polymerase chain reaction positive) patients were recruited and assigned to a '
'7-day CPM treatment (n=32) or placebo (PLB; n=13). Close safety monitoring of all patients '
'was conducted before and after administering the drug. The primary outcomes monitored were '
'time to symptom resolution (days), progression to hospitalization, emergency room visits, and '
'symptoms of the severity of the disease using a visual analog scale (VAS) on a scale of 1-10 '
'(no symptoms to worst symptoms). Results: The virus yielded a reduction in the assay such '
'that the CPM solution log reduction value was 2.69 and Remdesivir 0.12, demonstrating much '
'high antiviral activity of CPM. Results of the clinical phase demonstrate that VAS scores '
'between the groups were evident after using CPM for two days (day 3). The CPM group VAS were '
'significantly lower (P<0.001) starting from day three compared with day one. In contrast, '
'there were no statistically significant (P>0.05) changes in the PLB during the 7-day '
'treatment window. No subjects in the intervention group were hospitalized, while two in the '
'PLB required hospitalization (15.4%; X2=5.15, P=0.023). Besides some mild discomfort felt by '
'subjects immediately after applying the spray, the participants reported neither adverse '
'reactions nor side effects. Conclusion: If taken together, the results of the present '
'two-phase study point towards the conclusion that CPM is an antiviral agent that can be '
'administered intranasally to treat COVID-19 effectively.</jats:p>',
'DOI': '10.18103/mra.v10i3.2752',
'type': 'journal-article',
'created': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T04:22:10Z', 'timestamp': 1648873330000},
'source': 'Crossref',
'is-referenced-by-count': 4,
'title': 'Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical '
'Evidence',
'prefix': '10.18103',
'volume': '10',
'author': [ {'given': 'Marcos', 'family': 'Sanchez-Gonzalez', 'sequence': 'first', 'affiliation': []},
{'given': 'Jonna', 'family': 'Westover', 'sequence': 'additional', 'affiliation': []},
{'given': 'Syed', 'family': 'Rizvi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joselit', 'family': 'Torres', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gustavo', 'family': 'Ferrer', 'sequence': 'additional', 'affiliation': []}],
'member': '7483',
'published-online': {'date-parts': [[2022]]},
'container-title': 'Medical Research Archives',
'original-title': [],
'deposited': { 'date-parts': [[2022, 4, 2]],
'date-time': '2022-04-02T04:22:34Z',
'timestamp': 1648873354000},
'score': 1,
'resource': {'primary': {'URL': 'https://esmed.org/MRA/index.php/mra/article/view/2752'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022]]},
'references-count': 0,
'journal-issue': { 'issue': '3',
'published-online': {'date-parts': [[2022]]},
'published-print': {'date-parts': [[2022]]}},
'URL': 'http://dx.doi.org/10.18103/mra.v10i3.2752',
'relation': {},
'ISSN': ['2375-1916', '2375-1924'],
'subject': [],
'container-title-short': 'MRAJ',
'published': {'date-parts': [[2022]]}}
